James Pope, MD
Pulmonary Disease · Hartford, CTNPI 1558318808
Payments from drug & device makers
Across 657 payments — averaging $189.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$111K
- Mylan Specialty L.p.$6K
- GSK$3K
- Amgen$634
- Boehringer Ingelheim$516
- Mallinckrodt Hospital Products Inc.$436
- plus $2K from 25 others
What the payments were for
- Consulting fees$6,9756%
- Speaking & faculty fees$99,44780%
- Travel & lodging$4,0963%
- Food & beverage$13,99411%
- Education$1860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 206 | $111,422 |
| Mylan Specialty L.p. | 41 | $6,168 |
| GSK | 234 | $3,297 |
| Amgen | 25 | $634 |
| Boehringer Ingelheim | 22 | $516 |
| Mallinckrodt Hospital Products Inc. | 16 | $436 |
| Regeneron Healthcare Solutions, Inc. | 16 | $362 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $291 |
| Verona Pharma, Inc. | 10 | $253 |
| Viatris Specialty LLC | 11 | $221 |
| AbbVie(2 entities) | 8 | $173 |
| Insmed, Inc. | 7 | $133 |
| Jazz Pharmaceuticals Inc. | 5 | $113 |
| Electromed, Inc. | 11 | $110 |
| Novartis | 4 | $92 |
| Sunovion Pharmaceuticals Inc. | 6 | $64 |
| Harmony Biosciences LLC | 2 | $57 |
| Circassia Inc. | 3 | $50 |
| Pfizer | 3 | $48 |
| Advanced Respiratory, Inc | 2 | $34 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $30 |
| Johnson & Johnson | 1 | $24 |
| Grifols USA, LLC | 1 | $24 |
| Baxter Healthcare | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| Merck | 1 | $17 |
| Sanofi | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$124,698 in reported general payments places this provider in the 90th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 55 | $1,382,578 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 733 | $624,323 |
| TezspireTezepelumab-Ekko | 101 | $477,800 |
| OfevNintedanib Esylate | 19 | $250,931 |
| Fasenra PenBenralizumab | 11 | $63,101 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 87 | $60,004 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 95 | $57,746 |
| Breo ElliptaFluticasone/Vilanterol | 87 | $53,733 |
| Spiriva RespimatTiotropium Bromide | 51 | $41,468 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $18,876 |
| Spiriva HandihalerTiotropium Bromide | 13 | $18,652 |
| EliquisApixaban | 27 | $17,743 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $11,200 |
| Tiotropium Bromide | 11 | $10,908 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $10,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $3,297 | $739,784932 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $111,422 | $549,005216 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $516 | $311,27698 claims |
| PfizerEliquis | $48 | $17,74327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Hartford
- Raj ParikhHartford$419K
- Patrick TroyHartford$385K
- Jeffrey NascimentoHartford$213K
- Daniel GerardiHartford$156K
- John McArdleHartford$90K
- Anil MaggeHartford$74K
- Francoise RouxHartford$39K
- Eric ShoreHartford$35K
- John RussomannoHartford$18K
- Meredith HolubHartford$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.